Drug Profile
Research programme: cathepsin V inhibitors - Celera Genomics
Alternative Names: Cathepsin V inhibitors research programme - Celera GenomicsLatest Information Update: 05 Sep 2006
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Class
- Mechanism of Action CTSL2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group
- 28 Sep 2000 New profile